ANNUAL REPORT 2003-2004 L REPORT Cancer Cures On All Fronts

Cancer Cures On All Fronts
ANNUAL REPORT
2003-2004
THE UNIVERSITY OF CHICAGO CANCER RESEARCH CENTER
THE UNIVERSITY OF CHICAGO CANCER RESEARCH FOUNDATION

At the University of Chicago Cancer
Research Center, our mission is
to understand, cure and prevent each of
the scores of diseases we collectively call
cancer. We pursue this goal by promoting
collaboration among a diverse and dedicated
team of outstanding laboratory scientists,
caregivers, clinical researchers and trainees.
These partnerships help us develop solutions
tailored to the complexity of individual
cancers and the unique needs of each
patient. Our faculty and staff are dedicated
to mentoring and inspiring the investigators
of tomorrow while providing superior care
to the people of today.
Seeking
Cancer Cures
On All Fronts
1-2
3
5
9
13
16
21
24
Letters:
From the Director
From the President of the Foundation
Introduction:
UCCRC overview and its unique strengths
In the Lab
In the Clinic
In the Community
Benefactors
Foundation Boards and Auxiliaries
Financials

I
feel very privileged to introduce this year’s annual report and to thank you for your
dedicated, enthusiastic support. I also want to express my appreciation for your help
and kindness throughout my first six months as Director of our groundbreaking
organization. It has been extremely challenging to follow in the footsteps of our three
previous directors – John E. Ultmann, MD; Richard L. Schilsky, MD, and Nicholas J.
Vogelzang, MD – and interim director Everett E. Vokes, MD. I only hope that I can meet
the high standards they established.
I am also thankful for the support of my colleagues. We have a talented team of dedicated
researchers and clinicians with the expertise to push the boundaries of knowledge and
achieve fundamental breakthroughs in the prevention, diagnosis and treatment of cancer.
The cancer research community recognizes the pre-eminence of our members who have
had remarkable success in obtaining funding. Having grown our funding base for five
straight years, it now exceeds $101,000,000.
We are doing all we can to make our extraordinary group of professionals even stronger.
Our aggressive recruitment campaign is proving successful, in part, because of the generous
support of our donors. You can be sure that we will remain at the forefront of cancer research
as the pace of scientific discovery accelerates and the number of medical breakthroughs
multiplies.
A Message from the Director o f t h e U n i v e r s i t y o f C h i c a g o C a n c e r R e s e a r c h C e n t e r
We designed this year’s annual report to give you a sense of the significant progress being
made and the electrifying opportunities that lie ahead. Consequently, we have included
a brief overview of the some of the ways we are “seeking cancer cures on all fronts.”
Unfortunately, we could not include all the highlights of this year’s research. A complete
accounting would be far too long for this document; thus, we have provided only a few
examples of the many excellent efforts underway.
The report also surveys the many activities of the University of Chicago Cancer Research
Foundation and the participation of other donors and groups. As our Foundation President
Ruth Ann McGuinnis explains, philanthropy provides the seed funding necessary for
obtaining additional funding for truly revolutionary research. You enable us to engage in
research that will catalyze the discoveries of tomorrow.
Thus, I hope you will read this document with great pride knowing the vital role you play
in making this progress possible. You are the core group of supporters who help us meet
and overcome tough challenges, and we will be looking for you to come with us as we
move forward into a future of enormous promise. The opportunities are there. We intend
to pursue them vigorously, and, with your contributions and counsel, we will succeed.
Thank you for your support, your spirit and your sacrifices.
Respectfully,
Michelle M. Le Beau
Director, The University of Chicago
Cancer Research Center
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2004
1

T
his is a time of extraordinary promise in medical science, and the University of
Chicago Cancer Research Foundation is delighted to play a supporting role in
the scientific revolution that is transforming cancer care and prevention. At the
University of Chicago Cancer Research Center, the pace of discovery has quickened, and
years of diligent, visionary research are culminating in remarkable discoveries that offer
hope to cancer victims and their families.
As members of the Foundation, we are investors in innovation. We provide the Center
with funding that has a special value because it supports the preliminary research required
to obtain financing from other sources. In a sense, we raise the venture capital that gives
scientists and clinicians the freedom to boldly pursue their most promising insights. By
leveraging our contributions, the Center is able to create pioneering therapies and bring
their enormous benefits to patients and communities.
I am pleased to say that the Foundation raised $1,764,672 in funding in Fiscal Year 2003-
2004, exceeding last year’s record total by more than $180,000 and the previous year’s by
almost $300,000. That is a remarkable achievement, and we all owe a debt of gratitude to
the Foundation’s dedicated members and other generous donors.
A Message from the President of the Universit y of Chicago Cancer Research Foundation
The Foundation has been able to make significant progress even in difficult economic
times, in part, because it can point to a continuing tradition of research success. You can
be sure that the breakthroughs of the past year will facilitate our efforts in the decades to
come. Our confidence in the future is unshakeable.
Under the dynamic leadership of its new Director, Michelle M. Le Beau, PhD, the Center
has developed a comprehensive strategy designed to encourage greater collaboration among
researchers, attract new talent to the University of Chicago, and provide its members with
new assets to support their vital work. Dr. Le Beau has been a Center member for more
than two decades, a program leader for 13 years, and has chaired the Committee on Cancer
Biology for the last four years. The remarkable talents she brings to this position will serve
her well for this latest and most challenging phase in her career. We congratulate Dr.
Le Beau and pledge our unyielding support for her visionary strategy to enhance the
Center. Whether our contributions are used to recruit faculty or to equip labs in the new
research facility, you can be sure that we will play an important role in implementing her
plan. Together, we will help Dr. Le Beau and her team take the Center to the next level.
I encourage you to read this annual report carefully. Although it provides only a small
sampling of this year’s advances in fundamental science and clinical research, I am sure it
will fill you with great expectations for cancer prevention, diagnosis, and treatment. Your
contributions and commitment justify these high hopes. I thank each and every one of you
for your generous participation in our essential mission.
Sincerely,
Ruth Ann McGuinnis
President
The University of Chicago
Cancer Research Foundation

Cancer Cures On All Fronts
In the last 15 years, we have learned more about the scores of diseases that we collectively call cancer than in
the preceding 4,000. This enormous leap in knowledge has deepened our understanding of the complexity
of these diseases and underscored the importance of developing a broad range of strategies and solutions to
prevent, diagnose, and treat them.
At the University of Chicago Cancer Research Center (UCCRC), we attack these maladies on all fronts. Our
scientists and clinicians seek cancer cures in the lab, the clinic, and the community.
In the lab, scientists study these diseases at the molecular level to evaluate how a minute variation in a single
chromosome or gene can trigger a process leading to abnormal, devastating cell growth.
In the clinic, researchers apply the knowledge discovered in the lab to create and test promising new treatments
and procedures. They bring patients new hope as they analyze novel therapies for effectiveness and to
determine optimal dosages.
In the community, investigators implement new approaches to prevention, teach state-of-the-art diagnostics to
local physicians, and strive to eliminate health disparities separating one ethnic or social group from the
rest of the population.
Tradition, Teamwork and Translation
The UCCRC can pursue this comprehensive approach successfully, because it has the intellectual and
technical resources to excel in each of the three arenas. Moreover, its members share a common commitment
to build on the University of Chicago’s tradition of excellence, leverage the power of teamwork, and
translate fundamental scientific discoveries into practical applications designed to enhance patient care.
A Tradition of Excellence
For more than 100 years, University of Chicago scientists and physicians have consistently pushed the
boundaries of knowledge and transformed cancer care and prevention. In fact, their seminal discoveries
helped enable the development and introduction of the majority of the cancer treatments we use today.
We can trace the beginnings of chemotherapy, hormonal therapy, gene therapy and bone marrow
transplantation to the University of Chicago.
These discoveries earned worldwide recognition for the University. Charles B. Huggins, for example,
received the 1966 Nobel Prize for Physiology and Medicine for his fundamental work in hormonal
therapy. Dr. Janet Rowley’s groundbreaking research, which established the links between genetics and
malignancy, earned her a National Medal of Science and the 1998 Lasker Award for Clinical Medical
Research (informally known as the “American Nobel prize”). Dr. Rowley is a UCCRC member and the
Blum-Riese Distinguished Service Professor of Medicine.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
3

Elwood Jensen, PhD, the Charles B. Huggins Distinguished Service Professor Emeritus in the Ben May Institute
for Cancer Research, won the 2004 Lasker Award for Basic Medical Research as one of the three scientists whose
discoveries “revolutionized the fields of endocrinology and metabolism,” according to the award citation. Dr.
Jensen’s work enhanced the treatment and prevention of breast cancer. The fact that Dr. Jensen and Dr. Huggins
both successfully explored the potential of hormone therapy using different approaches underscores the value of
a research community that encompasses a diversity of perspectives.
This tradition of excellence is as vibrant today as it has ever been. The UCCRC has a global reputation for
superior research in advanced radiation treatments, excels in the development of novel anticancer drugs, brings the
enormous potential of advanced imaging to life, and leads the way in the emerging field of pharmacogenomics.
The Spirit of Teamwork
Pharmacogenomics combines the disciplines of medicine, genetics and pharmacology to study how a person’s
genetic makeup affects his or her body’s response to drugs. This new field offers the promise of developing therapies
that account for genetic diversity. Pharmacogenomics also provides an example of how the cooperative interaction
of researchers from diverse fields generate productive new approaches for attacking cancer.
Collaboration is fundamental to the mission of our University. The essence of its scholarly tradition is, in
the words of University President Don Michael Randel, the “great conversation” that cuts “across traditional
disciplines [and] creates not only new knowledge but whole new fields of knowledge.”
The University’s founders embraced collaboration as a core value and designed the campus to facilitate integrated
scholarship. Although the institution is among a handful of the world’s top research universities, it is still small
enough to promote ongoing interaction among a community of renowned scholars. Working side-by-side,
doctors, medical researchers, chemists, physicists, mathematicians, computer experts and environmental and
social scientists share expertise, ideas and insights in the search for cancer cures.
The design of the evolving campus continues to reflect this commitment to interdisciplinary research. When it
opens next year, the new Interdivisional Research Building (IRB) will bring biologists, physicists and chemists
together at one location. The IRB will also be the new home of the Ben May Institute. Construction will begin
soon on a second, interdisciplinary research facility: the New Research Building. The NRB will house the Center
and provide us with excellent opportunities to interact with colleagues throughout the University. With the Ben
May Institute in the IRB, the two adjacent buildings will become the nexus of cancer research. In addition to
fostering cross-disciplinary cooperation, these state-of-the-art facilities will strengthen our recruitment efforts.
Of course, we need to raise significant new funding to make this happen.
Translation: Bench to Bedside and Bedside to Bench
This power of proximity also plays a role in reinforcing another of the UCCRC’s greatest strengths: the translation
of lab breakthroughs into practical treatments.
The University of Chicago is one of a handful of research universities with the combination of resources and
personnel required to follow the process of drug discovery through the complete spectrum of clinical trials. The
Center and the hospitals work together to bridge basic and clinical research and deliver the latest therapies to the
bedside at a much faster rate. Our programs are genuinely “Bedside to Laboratory” and “Laboratory to Bedside.”
We are working just as diligently to bring the advantages of groundbreaking scholarship to the community.
The Cancer Risk Clinic, for example, works in local neighborhoods to identify families and individuals with an
increased threat of malignancy. The Clinic’s teams work with the patients developing strategies to lower risk and
to help them deal with the medical, psychological and social impacts of their conditions.
The Lab, the Clinic, the Community
From the physicist studying the dynamics of three-dimensional imaging to the epidemiologist evaluating the
recurrence of breast cancer in a single neighborhood, University of Chicago researchers are developing new
tactics to succeed in the war against cancer in all its forms. The members of the UCCRC understand that complex
problems demand multifaceted solutions and they aggressively strive to unravel the intricacies of these diseases.
They are attacking cancer’s many manifestations from all angles, and they are making significant headway in the
lab, the clinic and the community.

I
n the lab, our scientists explore the infinitesimal world of a single cell to understand the fundamental dynamics
of cancer and to design innovative ways to annihilate malignant cells while leaving healthy ones untouched.
As they probe the chinks in cancer’s defenses, UCCRC researchers are developing an arsenal of new procedures for
attacking these diseases from all directions. For example, they explore interactions between the immune system
and tumors with the expectation of enlisting the body’s own resources in the fight against malignancy.
Leveraging the Body’s Own Defenses
Albert Bendelac, MD, PhD, is studying a family of molecules that regulate the immune system’s attack
against cancer. His discoveries promote the development of a body of exciting new cancer treatments,
including vaccines and adjuvants.
Hans Schreiber, MD, PhD, investigates the fundamental mechanisms governing the immune system. One
of his objectives is to determine why some cancer cells are able to elude and survive the immune system’s
dragnet and continue to disseminate malignancy. Solving this problem would be an important milestone
in the creation of immunotherapies that could seek and destroy cancer cells that have already spread
throughout the body.
Killing Cancer from the Inside Out
Cancer Cures In the Lab
UCCRC scientists are also probing another potential weak point in cancer’s defenses: angiogenesis.
Angiogenesis is the process with which tumors induce existing blood vessels to sprout new capillaries,
thereby obtaining the blood they need to grow and thrive. By inhibiting vessel growth, therapies that block
angiogenesis deny tumors their vital nourishment, literally killing cancer from the inside out. Dr. Walter L.
Stadler, MD, and Gregory L. Karczmar, PhD, have formed a unique collaboration using advanced imaging to
investigate antiangiogenic drugs in the treatment of prostate and renal cancer. Their goal is to find new antitumor
agents that function by inhibiting blood flow to the tumor as well as identify new magnetic resonance
imaging (MRI) techniques for predicting which patients are most likely to benefit from such therapy.
Developing effective anti-angiogenic therapies, however, is not a clear-cut task. Tumors have many
mechanisms that they call upon in their relentless pursuit of growth through angiogenesis. A drug may
successfully inhibit one mechanism only to have another jump into the breach to initiate the process of
producing new blood flow.
Mark W. Lingen, DDS, PhD, employs traditional and state-of-the-art applications of biology, genetics,
biochemistry, and molecular biology to deal with the complexity of this challenge. He and his team
are searching for anti-angiogenic agents that can work in concert to effectively attack all the direct and
indirect mechanisms involved. He has discovered that evaluating the genetic fingerprint of a tumor
(genetic profiling) is a useful tool for determining which agents are able to combine forces in the fight
against angiogenesis. Dr. Lingen’s research is essential to the design of comprehensive attacks that can stop
angiogenesis in its tracks.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
5

The Genetics of Cancer
Advances in genetics – from the discovery of the chemical structure of DNA to the mapping of the human
genome – have had momentous impacts on cancer research. Cancer, after all, begins with genetic abnormalities
that destabilize the body’s controls regulating cell growth and division. Armed with technologies that allow
them to study cells at the molecular level, researchers can now pinpoint the changes to genes or chromosomes
that are the sources of malignancies.
Advances in genetics have had momentous impac ts on cancer research.
John D. Crispino, PhD, of the Ben May Institute for Cancer Research, has discovered a genetic mutation
that occurs in almost all cases of a form of leukemia that affects young patients with Down Syndrome. It
also appears in its earliest phase in patients who have a disorder that precedes the leukemia. This insight
may someday enable us to intervene and pre-treat this cancer.
Michelle M. Le Beau, PhD, identifies recurring chromosomal abnormalities in patients with cancer and
correlates them with physical and clinical aspects of their diseases. This information is used to determine
the most appropriate drugs for treating particular tumors and to better assess the unique hazards faced by
individual patients. Dr. Le Beau’s current research emphasis is secondary leukemia, which is an unfortunate
side effect of some cancer treatments. By delineating the etiology (or molecular basis) of the disease, she
hopes to develop procedures to identify patients at greater risks for contracting the disease and to minimize
its hazards.

Molecular Mechanisms and Cancer
Anning Lin, PhD, Marsha Rosner, PhD, and their laboratories are working together to leverage the
wealth of new information enriching our understanding of the underlying molecular mechanisms
of cells. They are examining new ways to initiate natural processes that attack cancer. For example,
their collaboration is responsible for exploring novel strategies for promoting apoptosis in tumor cells.
Apoptosis is genetically programmed cell death, which is the normal physiological process that eliminates
DNA-damaged, superfluous, or unwanted cells. Both Dr. Lin and Dr. Rosner are members of the Ben
May Institute, and they are enhancing the Institute’s superior reputation for basic scientific research that
is fundamental to our efforts to understand and treat cancer.
Geoffrey L. Greene, PhD, also contributes to the Ben May Institute’s tradition of excellence in
scientific research. He continues to make breakthroughs in our understanding of how female
steroid hormones regulate cellular growth in hormone-responsive tissues and cancers. This
research is helping us not only understand the processes that initiate breast cancer, but also
to develop novel drugs that can be used to treat and prevent breast and uterine cancers. Some of
these drugs might have application in hormone replacement therapy in postmenopausal women.
Modulating Gene Repair
Another promising research subject is the mechanics of DNA repair. Healthy cells can repair the
damage to DNA molecules, which sometimes occurs during the normal lifespan of a cell. DNA repair
helps prevent the inception of cancer because it mends mutations that, if not restored, could lead to
the disease. Unfortunately, this process can protect cancer cells themselves against the very treatments
designed to kill them. An example is radiation therapy, which works by attacking the DNA in tumor
cells. DNA repair can reverse the benefits of these therapies. Clearly, there are times in the fight against
these diseases when we want to facilitate DNA repair and other times when we want to inhibit it.
This is why Douglas Bishop, PhD, is intent on expanding our understanding of this process. He recently
setup a new method for studying BRCA1, a gene that plays a fundamental role in DNA repair, thus
preventing cancer. BRCA1 is best known for its causative role in familial breast cancer. The normal
BRCA1 protein helps repair DNA damage and avert cancer. People who inherit defective copies of this
gene have a high risk of breast cancer and other malignancies. Dr. Bishop’s research into this protein and
its role in DNA repair has significant implications for cancer treatment and diagnosis.
Chuan He, PhD, leads a research program that spans a broad range of chemistry and chemical biology.
He is probing the mechanism of DNA repair in the search for new DNA repair proteins that initially
recognize damage. M. Eileen Dolan, PhD, has also focused on DNA damage and repair. She and her
lab are developing modulators of chemotherapy that are being tested clinically as a means to inhibit
DNA repair and thus enhance the effectiveness of certain chemotherapy drugs. A chief emphasis of
her work has been on the decreasing toxicities associated with chemotherapy. Drs. He and Dolan have
joined forces to design better modulators based on the chemical reactions that occur in cells when DNA
is damaged and repaired.
Her objective is to identify the genes that can determine an individual’s susceptibility to DNA damaging
agents. She is also evaluating how genetic variation influences the effectiveness and toxicity of therapies
for individual patients. This information is proving to be extremely valuable in determining which
therapies to prescribe to specific patients and at what dosages.
From the Lab to the Clinic
Dr. Dolan is just one of many researchers at the UCCRC who are expanding our knowledge of cancer
and its dynamics. She and her colleagues are making breakthrough discoveries that build the scientific
foundations for numerous advances in the prevention, diagnosis and treatment of cancer. Moreover, they
are translating their successes from the lab into the clinic. Thus, they are working diligently to enhance
patient care while developing cancer cures that are more effective, less harmful, and increasingly precise
when attacking malignant tumors.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
7

Cancer Cures In the Clinic
Nobel Laureate and Ben May Institute for Cancer Research founder Charles B. Huggins, MD, affirmed
a simple message to his students: the battle against cancer begins with discoveries that illuminate
why organisms thrive and why they fail. Thus, cancer cures begin in fundamental research that
launches clinical research and culminates in superior cancer care. Whether in the lab or the clinic, our scientists
and clinicians share a common goal: to transform discovery into therapy.
Consequently, our researchers often have one foot in the lab and one in the clinic. Like Dr. Huggins, they
recognize the usefulness of collaborative research that involves scientists and clinicians. As a result, no clear,
bright line separates the lab from the clinic.
Bringing Advanced Therapies to Patients
Ben May Institute for Cancer Research investigator Thomas F. Gajewski, MD, PhD, and his team, for
example, explore ways to control, manipulate and enhance immune responses against cancer. Their
findings enable them to develop vaccines and other immune therapies that they first test in mice
bearing established tumors. Approaches that reduce tumors in animals become candidates for human
testing. Dr. Gajewski and his team have already shown tumor shrinkage in patients with a vaccine
against melanoma. They have new vaccines that are being investigated in patients with pancreatic
and kidney cancers. This work relies on the collaboration of basic immunology researchers, medical
oncologists, surgeons, and pathologists.
Clinical trials provide the means for bringing the benefits of their advanced research directly to the
patients who most need them. More than 1,000 patients participate annually in our clinical trials
program, which is one of most comprehensive and sophisticated in the world. We are one of only a
handful of institutions with the expertise, resources and capabilities to take oversight responsibility for
trials representing all three phases of clinical research. This three-phase process allows for the orderly
gathering of information, ensures patient safety, and maximizes therapeutic value.
A Three-Phase Process
Phase I studies involve the fewest number of patients. Their purpose is to determine how to administer
new drugs and what are the safest, most effective doses. Phase II trials continue to focus on safety and
begin the analysis of the effectiveness of innovative therapies. Phase III trials usually enroll numerous
patients and involve numerous institutions under the direction of a lead research center. These trials
compare experimental drugs, combinations of drugs or surgical procedures with existing therapies to
determine if innovations are superior to the current standards.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
9

Our most vital concern, of course,
is protecting the patient’s safety,
privacy and health, and we are very
careful to achieve the highest ethical standards
in all of our trials. In fact, Dr. Christopher
K. Daugherty’s research, which examines the
ethics of clinical trials in advanced cancer
care, is helping investigators maintain this
principled focus. Dr. Daugherty’s studies
analyze, in particular, doctor-patient
communication, decision making, and
issues of informed consent.
Ensuring Patient Safety
Research advances are making clinical trials safer and more beneficial for patients. Pharmacogenomics, for
example, enables researchers to identify individuals who are most likely to suffer severe adverse reactions
from the drug being tested. Our leadership in the study of cancer and genetics is an invaluable asset in
ensuring effectiveness of our clinical trials and in protecting participants. Diet, environment, lifestyle and
a myriad of other factors determine how individuals respond to cancer drugs, but genetics arguably is the
most powerful factor of all. As a drug enters the body, it reacts with many different proteins, producing
both therapeutic and harmful effects.
Since genes determine the structure of each protein, minor disparities in a patient’s DNA can cause major
differences in how his or her proteins react to a drug. That’s why a drug can be effective for one person and
ineffective for another. It’s also the reason that a drug can be perfectly safe for 99 patients but extremely
toxic for one.
Understanding Patient Variability
Mark J. Ratain, MD, has set the standard for studying and understanding human variability in responses
to drugs. He chairs the Pharmacogenomics of Anticancer Agents Research Group (PAAR) study. This
$14-million, four-year study is investigating how genetic differences affect an individual’s response to
cancer drugs. The team begins with human tissue samples to evaluate the diverse ways our bodies absorb,
distribute, break down and eliminate medications. The most promising compounds are then tested in
human trials. The ultimate goal of Dr. Ratain’s research is to help tailor medicines to a person’s unique
genetic make-up, which will ultimately make medicines safer and more effective for everyone.
Dr. Ratain is also the lead investigator on a Phase II trial of a new drug called BAY 43-9006 that has
demonstrated significant short-term benefits for patients with advanced kidney cancer. Less than 15
percent of patients with metastatic kidney cancer respond to standard immunotherapy. In the trial, 42
percent of patients had their tumors shrink at least 25 percent within the first 12 weeks.
National Cooperation
As chairman of the Cancer and Leukemia Group B (CALGB), Richard L. Schilsky, MD, oversees clinical
trials that are delivering results that are equally spectacular. The CALGB is one of ten national clinical
cooperative groups conducting Phase III clinical trials.

A recent CALGB study was so successful that the Data Safety Monitoring Board halted the trial
early, because it wanted to accelerate delivery of the treatment to all patients with early stage lung
cancer. The study, which enrolled 344 patients, found that adjuvant chemotherapy following surgery
decreased the risk of dying from lung cancer by 49 percent.
This is a major breakthrough in the treatment of a particularly deadly cancer that has been resistant to
treatment. According to the American Cancer Society, lung cancer is, by far, the most common fatal
cancer in men and women. It accounts for 32% of male cancer deaths and 25% of women’s deaths
from malignancy. Wendy Stock, MD, leads the correlative leukemia studies conducted by CALGB. She
studies the disease at the molecular level to evaluate treatment and to determine if any traces remain.
Robotic Surgery Photo: Dan Dry
Finding the Best Combinations
Everett E. Vokes, MD, is the principal investigator in a cooperative agreement with the National
Cancer Institute (NCI). (A cooperative agreement is a very specific funding mechanism that involves
extensive programmatic involvement between the recipient and the NCI.) Only seven other scientists
in the nation have this distinction for Phase II trials. Dr. Vokes’ research focuses on malignancies of
the chest including lung, chest and esophagus, as well as advanced head and neck cancer. His team is
proving the value of therapies that use chemotherapy in combination with radiation. This approach
has proven successful in treating cancers that are resistant to more traditional therapies.
Ralph R. Weichselbaum, MD, and his team are exploring the use of radiation in combination with
other treatments. Dr. Weichselbaum is using a radiation-activated gene to harness the power of a
cancer killing protein called tumor necrosis factor (TNF). The body naturally produces TNF, but it is
often lethal when introduced as a therapeutic agent. When attached to the radiation-activated gene,
TNF can be targeted precisely, enabling it to seek and kill tumors without affecting healthy tissue.
This approach has proven its value in treating breast and pancreatic tumors, and trials are underway
to test its effectiveness against pancreatic, esophageal, rectal, and head and neck cancer.
Hedy L. Kindler, MD, is evaluating various combinations of drugs in the battle against pancreatic cancer, a
particularly deadly form of cancer. One successful trial investigated the use of an experimental medication,
bevacuzimab, in conjunction with a standard chemotherapy drug, gemcitabine. (Bevacuzimab inhibits
the growth of blood vessels, which supply the tumors with nutrients.) The striking results of the Phase
II trial set the stage for a randomized Phase III trial comparing the effectiveness of the bevacuzimabgemcitabine
combination with gemcitabine alone. It also led to the initiation of several Phase II trials
evaluating bevacuzimab in combination with other agents and radiation.
In the Surgical Theater
The surgical theater is another location where
we are developing improved cancer treatments.
Arieh Shalhav, MD, is employing new robotic
systems to remove cancerous prostate glands
with less pain, smaller scars, and minimal
blood loss. He is using this innovative surgery
to increase continence and erectile functional
results and shorten recovery time. Patients
typically require six weeks of recovery before
they can resume normal activities following
traditional prostate surgery. The comparable
recovery time for robotic surgery is one week.
Dr. Shalhav and his colleagues employ their curiosity
and extraordinary expertise to transform
scientific discoveries into practical applications.
Their efforts in the clinics effectively deliver on
the promise of the revolutionary insights made
in UCCRC labs.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
11

Building photos: Ellen Ryan, Jim Wright

Cancer Cures In the Community
In the community, we bring our resources and expertise into neighborhoods and engage in community-based
research in partnership with local individuals, groups and institutions. Our programs help ensure that all
populations benefit from the fruits of our research. They bring clinical, biological, psychological and social
scientists together and help them target their efforts in controlling and preventing cancer.
Understanding Population Differences
The Center for Interdisciplinary Health Disparities Research, for example, pursues a collaborative
approach to examine population health and to evaluate and eliminate group differences in health. In
the first five years, the Center is focusing on understanding population differences in the incidence of
and the genetic and environmental factors that contribute to breast cancer in Caucasians, women of
African descent living in America and women native to Nigeria.
Sarah Gehlert, PhD, an associate professor at the School of Social Service Administration, where she serves
as Deputy Dean for Research, and the Institute for Mind and Biology, leads a diverse team of scientists from
the Biological Sciences and Social Sciences Divisions and the School of Social Service Administration.
This collaborative approach is creating an integrated, comprehensive analysis of the many factors - social,
behavioral, and biological - that are potential causes of the health disparities within diverse communities.
UCCRC members lead the four teams and two cores pursuing the specific aims of the research center.
Martha K. McClintock, PhD, and her team are comparing gene regulation in mammary tumors and
the ovarian function of socially isolated and group-living rats. They are using an animal model of social
regulation of mammary tumor biology developed in her laboratory.
Neighborhood Outreach
In the Center’s first year, Dr. Gehlert’s team conducted community-based focus groups in the 15
neighborhood areas of the South Side that are the focus of the Center’s investigations. Their objectives
were to elicit input on breast cancer and its treatment and to explore the suitability of the project’s central
constructs and measures with community stakeholders. Suzanne Conzen, MD, and her colleagues are
employing rodent models of human breast cancer to investigate the effects of social isolation on the rate
of tumor growth, chemotherapy, and chemoprevention effectiveness.
Local and International
In years 2-4 of the project, Olufunmilayo F. Olopade, MBBS, Dr. Gehlert and their colleagues will
work with African-American women living in the 15 South Side neighborhoods and women in Ibadan,
Nigeria. Since these two groups of women with similar genetics live in very different environments, this
comparative analysis will be useful in determining the relative roles of genetics and stress in the early
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
13

onset of breast cancer. Dr. Olopade’s team will study the molecular characterization of patient samples in
these two groups. Dr. Gehlert’s group will examine the influence of social and behavioral factors.
The Tissue Core Laboratory led by Thomas N. Krausz, MD, FRCPath, and Maria Tretiakova, MD, PhD,
is responsible for analyzing the mammary tissue for the Center. They utilize the extensive experience of
the Human Tissue Resource Core of the Department of Pathology. The University of Chicago has more
than 10 years of experience with breast cancer tissue collection and examination, having more than 5,000
archived diagnostic cases and over 150 fresh frozen samples. Dr. Gehlert leads the project’s administrative
core.
The Cancer Risk Clinic
Dr. Olopade is also the Director of the Cancer Risk Clinic. This diagnostic and preventive care program
offers individuals and families the opportunity to assess their likelihood of acquiring cancer. Teams of
experts – physicians, social workers, nurses and genetic counselors – work closely with patients and their
families assessing risk and developing strategies for prevention.
Community Partnerships
Another way the UCCRC delivers the fruits of its research directly to local communities is through
partnerships with health professionals outside the University. Our association, for example, with Little
Company of Mary Hospital Cancer Center in Evergreen Park, Illinois, delivers the advantages of a
university-based cancer program to the residents of Chicago’s southwest neighborhoods and suburbs. It
also provides them with easier access to clinical trials and the promise of investigational therapies.
Sharing expertise and research findings with community physicians is, of course, invaluable in translating
discovery into application. As a leader in advanced imaging (see next page), the UCCRC strives to help
general radiologists take advantage of the new imaging techniques and computer-assisted diagnosis that are
so helpful in the early detection of cancer. That is why physician researchers Gillian Newstead, MB, ChB,
FACR, and Robert A. Schmidt, MD, are developing an intensive training program for radiologists, which
will enhance their skills in reading magnetic resonance imaging (MRI), mammography, and ultrasound
images.
These are just a few of the ways the UCCRC and the University of Chicago are establishing productive
links with the surrounding neighborhoods and communities. We are committed to ensuring that the
people of the Chicago metropolitan area have access to the state-of-the-art medical care available at one of
the world’s premiere research, teaching and medical institutions.

Exploring the Potential of Advanced Imagery
The UCCRC is at the forefront of the radiology revolution that is transforming cancer care. Extraordinary
advances in imaging pioneered at the Center are enabling specialists to diagnose cancer in its early, less
harmful stages and attack cancerous tumors with greater precision.
For example, Gregory L. Karczmar, PhD, Gillian Newstead, MB, ChB, FACR, and their colleagues are exploring
an enhanced form of magnetic resonance imaging (MRI). High spectral and spatial resolution MRI is proving
instrumental in the early detection and staging of breast cancer. Dr. Karczmar and Milica Medved, PhD, are
pursuing another new technology that will likely prove invaluable in early diagnosis of breast cancer. The scans
they have produced using three-dimensional MRI reveal breast tissue with extraordinary clarity.
The UCCRC is also pushing the boundaries of computer-aided diagnosis (CAD). These sophisticated technologies
give radiologists a significant advantage in the vital and difficult task of image interpretation. Identifying lung
cancers through visual interpretation is very challenging. For this reason, Samuel Armato III, PhD, and Kunio
Doi, PhD, are developing automated techniques to identify lung nodules in computerized tomography (CT)
scans. (X-ray Tomography produces three-dimensional images of internal structures of the body.)
T h e U C C R C is pushing the boundaries of computer-aided diagnosis.
Robert M. Nishikawa, PhD, Ingrid Reiser, PhD, Maryellen Giger, PhD, and their colleagues are investigating
computerized detection of mass lesions on breast tomosynthesis images. Breast tomosynthesis is a promising
new technology that offers a three-dimensional perspective. Conventional mammography, which is twodimensional,
often results in false positives and negatives because overlapping breast tissues can either obscure
or mimic cancers.
Dr. Giger, Dr. Nishikawa, Yulei Jiang, PhD, and their colleagues are working with mammographers to
translate their multimodality breast imaging workstations to the clinical arena for evaluation. Developing
optimal methods for combining computer output from the analysis of multiple images and presenting the
information to the radiologist are crucial steps in CAD research.
Drs. Armato and Heber MacMahon, MD, are developing automated methods for comparing multiple chest
radiographs. Clinicians often use multiple images of the same patient to identify changes in anatomy and
pathology. Drs. Armato and MacMahon are evaluating a technique called temporal subtraction (a procedure
for layering images) to accurately integrate serial radiographs and help radiologists identify subtle, but critically
significant changes.
Xiaochuan Pan, PhD, and colleagues have made significant contributions to developing high-quality CT
images. These new concepts and algorithms facilitate the design of innovative imaging protocols that may
have significant clinical implications, e.g., breast imaging, liver imaging, and cardiac imaging.
Our imaging researchers are taking full advantage of new technologies that offer enormous promise in
supporting our search for cancer cures. They are using advanced imagery to unravel cancer’s complexity.

The University of Chicago Cancer Research Center
thanks those who contributed in 2003-2004 to cancer and cancer-related programs at the University of Chicago.
Diamond Circle
$250,000 - $1,000,000
Thomas J. Duckworth
and Connie Duckworth
The UCCRF Women’s Board
Sapphire Circle
$100,000-$249,999
The UCCRF Associates Board
Ruby Circle
$50,000 - $99,999
Driehaus Capital Management, Inc.
Charles Hammersmith &
Carol Hammersmith Family Foundation
Richardson, Patrick, Westbrook
& Brickman, L.L.C.
The UCCRF Auxiliary Board
The V Foundation
Platinum Circle
$25,000 - $49,999
Mr. and Mrs. Jeffrey Diermeier
Exelon Corporation
Klein Tools Charitable Foundation
Gold Circle
$10,000 - $24,999
Amgen, Inc.
John W. Anderson Foundation
Banc of America Securities, LLC
C N A Foundation
Mr. and Mrs. Benjamin D. Chereskin
Ms. Elizabeth I. Crown
and Mr. William Wallace
Mr. and Mrs. Andrew Da Miano
Enivar Charitable Fund
Mr. Peter A. Ferro, Jr.
Mr. and Mrs. Richard Halpern
Mr. and Mrs. Charles Harrold III
Mr. and Mrs. Steven Helms
Junior Cancer League
Kadrovach-Duckworth Family Foundation
Charles S. Lazerwitz Charitable Trust
The Lazzara Family Foundation
Marsh USA Inc.
Mr. and Mrs. Bernard D. Meltzer
JP Morgan
Motorola, Inc.
Paramount Pictures
Mr. and Mrs. Carl H. Pearson
Frederick H. Prince Trust/
Prince Charitable Trusts
Riviera Country Club & Sports Center
Mr. and Mrs. Michael Werner
Silver Circle
$5,000 - $9,999
Mr. and Mrs. James N. Bay, Jr.
Margaret and Lawrence Benjamin
William Blair & Company
William Blair & Company Foundation
Mr. and Mrs. Frank S. Brumfield
Mr. and Mrs. Harris Brumfield
Mr. and Mrs. Richard C. Carr
Mr. William J. Cortesi
Mr. Lambertus M. De Kool
Mr. and Mrs. Richard L. Duchossois
Mr. and Mrs. Ronald Duitsman
Gillespie Pontiac
K-Five Construction Corporation
Mrs. Michael Klein
Otto W. Lehmann Foundation
Mr. Laurence Lewis
Modestus Bauer Foundation
Moneris Solutions Inc.
Mr. and Mrs. David Nuelle
Mr. and Mrs. Thomas Reusché
Mr. and Mrs. Robert K. Robinson
Mr. and Mrs. Paul Rubschlager
Mr. Scott C. Schweighauser
and Ms. Elizabeth J. Ellrodt
Stuart-Rodgers Ltd.
Whole Foods Market Group, Inc.
Mr. and Mrs. Richard M. Woldenberg
Bronze Circle
$2,500 - $4,999
Mr. and Mrs. J. Douglas Bacon
Estate of Lillian Z. Bronkhurst
Cosmopolitan Bank & Trust
Mr. and Mrs. Michael Crane
Ms. Rebecca Davidson
and Mr. Richard Geddes
Duk Young Foundation
The Gillette Foundation
Mr. Austin L. Hirsch
and Ms. Beth Gomberg-Hirsch
Mr. and Mrs. William Hokin
Keystone Industries/
French Dressing Jeanswear
Mr. and Mrs. Donald A. King, Jr.
Ms. Jody Krug and Mr. Gerard Schulte
Ms. Amy Mazzolin
Mr. J. Clifford Moos
Mr. Stephen D. Nechtow
Mr. Alan Oremus
Reese McMahon, L.L.C.
Mr. and Mrs. Rex Sessions
Mrs. Lorraine Vandenbergh
Winston & Strawn LLP
Mr. and Mrs. James R. Woldenberg
Founders
$1,000 - $2,499
Mr. and Mrs. William Adams IV
Mr. and Mrs. Richard J. Almeida
Mrs. Alexander Anagnost
Mr. and Mrs. John Atchison
Mr. and Mrs. Chris Barber
Bay’s Corporation
Blitstein Family Foundation
Mr. and Mrs. Darcy Robert Bonner
Mr. and Mrs. Don Borzak
Mr. and Mrs. James Brady
Mr. and Mrs. Hardy Brumfield
Mr. and Mrs. John A. Buck
John & Jacolyn Bucksbaum Charitable Fund
Mrs. Bernard Burnstine
Mr. and Mrs. John Burnstine
Cancer Research Foundation
Mr. Alvin Chereskin
Mr. and Mrs. Neil Coleman
Mr. and Mrs. Robert Conrad
Mr. and Mrs. J. Patrick Corsiglia, Jr.
Mr. and Mrs. Oscar Cozzini
Mr. and Mrs. Richard W. Cusack
Mr. and Mrs. Thomas C. D’Aprile
Mr. and Mrs. Theodore K. Davis
The James and Judith K. Dimon Foundation
Mr. and Mrs. Matthew A. Fisher
Mr. and Mrs. Timothy Flood
Gorter Family Foundation
Mr. and Mrs. Freeman F. Gosden, Jr.
Thomas & Kathleen Grusecki Foundation
Mr. and Mrs. Raj Gupta
Mr. and Mrs. Thomas Hardin
Mr. and Mrs. Robert Hartman
Mr. William H. Hartz, Jr.
Mr. and Mrs. Christopher K. Hehmeyer
Hunckler Family Foundation
Iglewski Family Foundation
Estate of Sara Jacobson
Mr. and Mrs. Steven Edward Johnson
Mr. and Mrs. R. Stuart Johnstone
Joy Foundation
Mrs. Denis S. Karnosky
Mr. and Mrs. Thomas Eric Kilcollin
Mr. and Mrs. Gilbert W. Kurschner, Jr.
Mr. and Mrs. Tom Leahy
Ms. Elizabeth J. Martin
and Mr. George Egofske
Marziani Enterprises, LLC
Mr. and Mrs. Andrew R. McGaan
Mr. and Mrs. Patrick McGarvey
Mr. and Mrs. Michael McGuinnis
Ms. Noreen McGuire and Mr. Chad Schultz
Mr. and Mrs. McKay McKinnon
Mr. and Mrs. Edward J. Miller
Mudd Family Foundation

Mr. and Mrs. Robert Mueller
Mr. and Mrs. Timothy R. Mullen
Mrs. Evelyn H. Nathanson
Niamogue Foundation
Ms. Evelina Saliszewski and
Family
Mr. Daniel E. O’Neil
Ms. Mary Bliss Packer
Beth and Harvey Plotnick
Mr. Thomas S. Postek
Ms. Abbie Price
Pullman Bank
A. Frank and Dorothy B.
Rothschild Fund
Mr. Robert J. Sanborn
Mr. Scott Sauer
Mr. and Mrs. Frank C. Schell III
Mr. and Mrs. James Schink
Mr. and Mrs. Jeffrey S. Sharp
Mr. and Mrs. Brian P. Simmons
Mr. Gerald D. Skoning
Ms. Marilyn K. Straus
Sunset Food Mart, Inc.
Townsend Family Foundation, Ltd.
Mr. and Mrs. Barton G.
Tretheway
Mr. and Mrs. Timothy H. Ubben
Mr. and Mrs. Gary Verhoeven
Dr. and Mrs. Nicholas Vogelzang
Mr. and Mrs. Keith Ward
Mr. and Mrs. William Wardrop
Samuel Weinstein Family
Foundation
Mr. and Mrs. Donald J. Weiss
Benefactors
Under $1,000
Mr. and Mrs. Gustavo O. Abello
ABN Amro Plaza Hines
Operations Team and
Management Team
The ABN Amro Team
Mr. Rodney Abrams
Mr. and Mrs. Jon M. Abt
Mrs. Allan H. Adelman
El Adobe Corporation
Agape Foundation
Mr. James Agoranos
Mr. Milton Alexander
Charlene and Richard Alexander
Mr. and Mrs. Nick Alexos
Mr. and Mrs. Ronald J. Allen
Allstadt Hardin Foundation
Dr. and Mrs. Stephen Alport
Altair Advisers, LLC
Ms. Marilyn K. Alter
American Express Foundation
Ms. Jacqueline Annes
Mr. Thomas Anselmo
Mr. and Mrs. Larry Antonatos
Ms. Helena B. Appleton
Ariel Capital Management, Inc.
Ms. Dorothy Ascher
AT&T Community Griving
Program
Mr. Erwin K. Aulis and Ms.
Sharon V. Kristjanson
Ms. Marta Holsman Babson
Mrs. Doris Baer
Ms. Jeanne Baron
Barry Regent Quality
Dry Cleaners
Ms. Jean M. Barry
Mr. Alan M. Bartelstein
Bill Bartholomay Foundation
Mr. and Mrs. Steve Bartram
Ms. Margaret C. Bass
Ms. Kathy DiBianca Battle
Mr. and Mrs. John Bauer
Mr. and Mrs. Roger Baum
Mr. and Mrs. Richard L.
Baumgarten
Mr. and Mrs. Michael Bavcevic
Mr. Grant Bay
Mr. and Mrs. James R. Beach
Mr. and Mrs. Irwin Bear
Mr. and Mrs. Kevin Bedell
Mr. and Mrs. Stephen Bedell
Mr. Ivan Belan
Beliard, Gordon & Partners, Ltd.
Mrs. Robert R. Bell
Mr. and Mrs. Michael J. Bello
Mr. and Mrs. William Belman
Dr. and Mrs. Anthony Benard
Mrs. Gail Kirk Bennett
Mr. Eugene Bensinger and
Ms. Lynn Straus
Ms. Bonnie J. Benson
Mrs. R. Ford Bentley
Mr. James L. Berg
Mr. Todd Berger
Mr. and Mrs. Stephen L. Bergman
Mr. and Mrs. Arthur Berman
Dr. and Mrs. Anthony Bernard
Ms. Rose L. Bertrand
Ms. Bessie C. Betzelos
Ms. Greta L. Bilodeau
Mr. and Mrs. Ed Bjorncrantz
Ms. Jennifer Blankenship
Mr. and Mrs. Stanley Block
Ms. Michelle A. Boardman
Mr. and Mrs. David Bomier
Mr. and Mrs. Scott Bondurant
Ms. Suzanne Boren
Mr. and Mrs. Paul Borggren
Mr. and Mrs. James Borovsky
Ms. Janna Bounds
Mr. and Mrs. James Boyle
Mr. Bruce C. Boynick
bp Petroleum Products
Ms. Colleen Kenney Bracco
Ms. Fanchon Bradford
Mrs. Adelaide B. Brady
Mr. Timothy D. Brandhorst
and Ms. Amy Ostrander
Ms. Anne K. Brennan
Mr. and Mrs. Stephen J. Brewster
Mrs. Eric Brezina
Ms. Mary Brigden
Ms. Sharon L. Brix
Ms. Ellen L. Brouwers
Ms. Myra J. Brown
Mr. and Mrs. Murray Brown
Kathleen J. Brown &
Karl Oestrerch IV
Dean V. M. Brown
Ms. Julia Colman Browne
The Bertha & Henry Brownstein
Foundation /Carol and
Brian Brownstein
Mr. John S. Bubula
Sandy and Beth Buchsbaum
Mr. and Mrs. Ronald Budil
Ms. Dawn L. Budorick
Mr. and Mrs. Ted Buenger
Mr. and Mrs. Kevin T. Buggy
Mr. Friedrich H. Burian
Mr. and Mrs. Ray Burton
Mr. and Mrs. Michael J. Busch
Mr. and Mrs. A. Bradley Busscher
Mr. John Wm. Butler, Jr. and
Mr. John M. VanderLinden
Ms. Ann M. Byrne
Ms. Mary Ellen Cagney
Ms. Annette Calderwood
Mr. and Mrs. Amedeo L. Cappola
Ms. Elizabeth M. Carey
Mr. Paul E. Carey
Ms. Marybeth O. Carlson
Ms. Bonnie Carmell
Mr. Robert F. Carr III
Ms. Susan C. Carter
Mr. John Casey
Ms. Jeanne D. Cavanagh
CCTO
Mr. Frank D. Cella
Ms. Jessica Cesaroni
The Chavarria Family
Mr. and Mrs. James Cherney
Ms. Joan S. Cherry
Dr. Kristina Orfali and
Dr. Pierre Chiappori
Choco-Logo Confectionery
Design
Mr. and Mrs. Robert B. Chodos
Ms. Louise E. Christensen
Christie’s Incorporated
Don and Lois Chudacoff
Mr. and Mrs.Gregory Chun
Ms. Nicole Cirrito
Mr. and Mrs. Charles F. Clarke III
Ms. Nancy Coaker
Ezra and Michelle Cohen
Ms. Georgia Ann Cohen
Mr. Zane M. Cohn
Ms. Elaine Stone Colburn
Ms. Carol Cole
Dr. Geraldine Balut Coleman
Computer Associates
Mr. and Mrs. Kevin E. Condron
Mrs. Robert A. Conger
Mr. and Mrs. Kevin A. Connellan
Mr. and Mrs. Matthew Conti
Mr. and Mrs. Fred Cook
Corley Financial Corporation
Ms. Holly Cortes
Mr. and Mrs. Richard L. Cosenza
Ms. Margaret T. Coty
James and Kathleen Cowie
Mr. and Mrs. David Cox
Lawrence J. Crandus
Mr. and Mrs. Harold D. Crandus
Mr. and Mrs. William A. Crane
Creative Systems Corp.
Mr. Joseph Creed
Mr. Melford L. Crisman
Ms. Phyllis J. Crockett
Mr. and Mrs. Michael Crouch
Mr. and Mrs. Robert C. Crowe
Ms. Teresa M. Cullen
Mr. and Mrs. John Cullerton
Mr. Robert W. Culver, Jr.
Mr. and Mrs. David P. Currie
Ms. Patricia M. Curtner
Ms. Deborah A. Cyburt
Mr. and Mrs. Joseph A. D’Adamo
Ms. Angela Dansby
Ms. Marianne Smith Davidson
Ms. Jeanie Davis
Mr. and Mrs. Richard K. Deboer
Ms. Susanna Decker
deGiulio kitchen design, inc.
Delavan Community Chest
Mr. and Mrs. Glenn A.
DeMichele
Mr. and Mrs. Charles Demirjian
Mr. and Mrs. John W. Derse
Ms. Kathleen DeVine and
Mr. Neil Brilliant
Mr. and Mrs. David W.
Devonshire
Mr. and Mrs. Robert Todd
DeYoung
Ms. Christine Dias
Mr. Michael Diaz
Mr. and Mrs. W. Brinkley
Dickerson, Jr.
Ms. Wanda C. Dill
Divane Bros. Electric Co.
Mr. John W. Dixon
Mr. and Mrs. Walter J. Dobransky
M. Eileen Dolan, Ph.D.
Mr. and Mrs. John J. Dombek, Jr.
R. R. Donnelley, Mendota
Division
The Stefan Doser Family
Ms. Michelle S. Drabin
Ms. Elvy Leake Draft
Mrs. Helene Dubow
Mr. George E. Duchossois
Mr. and Mrs. Richard F. Duffy
Mr. and Mrs. Peter R. Dunne
Rod and Joan Durgin
Mr. and Mrs. John R. Dykstra
Mr. and Mrs. Reed H. Eberly
Mr. Richard G. Eckelkamp
Ms. Lynn Eikenbary
Ms. Judy A. Eisentrout
Mr. and Mrs. Thomas P. Eiter
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
17

Electronic Business Equipment
Marguerite C. Emanuel & Family
Mr. and Mrs. Ross D. Emmerman
Encore Marketing International Inc.
Environments By Design
Ms. Judith J. Erfurth
Mr. and Mrs. James Esser
Mr. and Mrs. Donald Eugenio
Mr. and Mrs. Gary Eve
Ms. Marcia R. Evenhouse
Mr. and Mrs. Garry Fagan
Mr. and Mrs. Eugene Fama
Mr. and Mrs. William Farago
Ms. Kari Farkvam
Ms. Shelley MacArthur Farley
Farm Trace Home Owners
Association
Boyd and Lenore Farmer
Ms. Carolyn P. Faust
Ms. Mary Ellen Faust
Ms. Kathy Feiger
Mr. and Mrs. Arthur Feiner
Mr. and Mrs. Gary Fencik
Mr. and Mrs. Richard Feingold
Mr. and Mrs. K. J. Fessler
Fidelity Investments
Mr. and Mrs. Larry Field
Dr. and Mrs. Anthony G. Finder
Mr. Thomas L. Finkbiner
Ms. Linda Finkel
Finnladies of Chicagoland
Ms. Marie L. Fioramonti
Mr. and Mrs. H. Barney Firestone
First Data Western Union
Foundation
Barry and Cheryl Fisher
Dr. and Mrs. Frank W. Fitch
Fitzgerald & Adzia
Mr. Scott Fitzgerald
Ms. Kathleen C. Fitzgerald
Ms. Jeanne P. Flannery
Mr. and Mrs. Robert Fleck
Ms. Teresa M. Fleischman
Mr. and Mrs. Richard S. Fleisher
Mrs. Fahey Flynn
Ms. Louise Folkman
Mr. and Mrs. Douglas Foster
Mr. James D. Foster
Mr. and Mrs. David W. Fox
Ms. Susan Frank
Mr. and Mrs. Philip Franklin
Ms. Christine C. Franklin
Ms. Lynn Fredrick
Mr. and Mrs. Louis E.
Freidheim, Jr.
Mr. and Mrs. Frank O. French
Mr. and Mrs. John E. Freund
Mr. and Mrs. Edward Freundlich
Ted and Sylvia Fried and Arnold
Friedman, Goldberg, Mintz
& Kallergis, LLC
Mr. and Mrs. Joseph G. Friedman
Friman & Stein, Inc.
Mr. and Mrs. Sidney Frisch
Ms. Elise W. Frost
Mr. and Mrs. William K. Fuller
Mr. and Mrs. Donald E. Gaines
Ms. Katie Gancer
Ms. Amy Gardiner
Mr. and Mrs. Scott Garell
Ms. Sharon Garell
Ms. Judie Ann Garver
Mr. and Mrs. James B. Gaw
Mrs. Martha F. Gearhart
Mr. James I. Gelbort
Ms. Hope F. Geldes
Ms. Brenda Gerardi-Bradshaw
Ms. Andrea O. Gerow
Ms. Nancy A. Gerstadt
Gibson Couture Cleaners, Inc.
Mr. R. Scott Gill
Mr. and Mrs. Edward Gillette
Mr. and Mrs. Jerry Goldberg
Mr. and Mrs. Dennis K.
Goldman & Family
Adam and Jessica Goodman
Mr. and Mrs. James S. Gordon
Mr. and Mrs. Robert Gorman
Mr. Michael Graff
Ms. Carrie S. Grant
Mr. and Mrs. Donald Grauer
Mr. and Mrs. Howard Green
Ms. Linda A. Green
Mr. and Mrs. David Greenberg
Dr. and Mrs. Geoffrey L. Greene
Mr. and Mrs. John K. Greene
Mrs. Ronald Greenspon
Ms. Bobbie Gregg
Mr. and Mrs. Daniel R. Gregus
Dr. Elise S. Grimes
Mr. and Mrs. David Grumhaus, Jr.
Ms. Kristen A. Guggeis
Hem and Asha Gupta
Mr. Daniel Gutman
Mr. and Mrs. Albert Hackett
Ms. Christine A. Hague
Mr. and Mrs. Brian Hahn
Mr. and Mrs. Bruce Halbeck
Dr. Denise D. Hale
Mr. Gary Hale
Mr. Jack L. Hallett
Mr. and Mrs. Thomas Hall
Mr. Howard V. Handler
Ms. Pamela Hanratty and
Mr. Jeff Coburn
Ms. Monica McCue Hansen
Mr. and Mrs. Gregory Hanson
Ms. Georgia D. Harbin
Ms. Roberta M. Hard
Mr. and Mrs. John Hardin
Mr. and Mrs. Sherman Harmelin
Ms. Kathleen J. Harmon
Mr. Robert T. Harrington II
Ms. Rosemary Harrington
Mr. and Mrs. Sheldon T. Harris
Mr. David Hartsell and
Ms. Wendie Reece
Ms. Winifred Hayes
Ms. Hillary Hecktman
Terry Heilman and Christine
Gronkiewicz
Mr. and Mrs. Frank G. Heino
Mr. and Mrs. David B. Heller
Heller Lumber Company
Mr. Steve T. Helms
Mr. Lewis C. Henderson
Ms. Lesli K. Henderson
Ms. Alicia C. Henneberry
Ms. Amy M. Herron
Mr. Leo F. Hickman
Ms. Katherine R. Hill
Mrs. Ellen Hirsch
JoAnn and Tim Hirsimaki
Mr. Robert T. Hofmann
Mr. Gerald C. Hoglund
Mr. Thomas Hoglund
Mr. and Mrs. Willard Hollinger
Honeywell International
Foundation
Mr. and Mrs. Gustav Horschke
Sheara and Larry Horwich
Ms. Phyllis Horwitz
Mr. Jonathan Howard
Mr. Frank B. Hubachek, Jr.
Ms. Carolyn L. Hubbard
Mr. and Mrs. Michael E. Hughes
Mr. and Mrs. Arnold Huhtelin
Mr. and Mrs. Kenneth Humes
Mr. and Mrs. William B.
Hummer
Hylan Design, Ltd.
Ms. Donna Krier Ioppolo
Mr. and Mrs. Timothy Irons
Mr. and Mrs. Robert T. Isham, Jr.
Ms. Victoria Jackson
Ms. Ethel Lee Jaffe
The Jaffee Foundation
Jameson Realty Group, Inc.
Mr. and Mrs. James R. Jankowski
Mr. and Mrs. Charles L. Jarik
Ms. Anne K. Jensen
Ms. Eunice C. Joffe
Mr. Bruce M. Johnson
Mr. and Mrs. Wayne M. Johnson
Ms. Nancy Josephs
Ms. Michele M. Joubert
Ms. Betty Z. Kahnweiler
Eeva Kallio
Ms. Ruth Kaminer
Mr. and Mrs. Thomas G. Kamp
Mr. Jeffry W. Kamrow
Temma and Lynn Kanowith
Mr. and Mrs. David Kaplan
Ms. Kristen A. Karczewski
Mr. Howard Kaufman
Mr. and Mrs. Robert W. Kaufman
The John L. Keeley, Jr.
Foundation
Ms. Carol W. Keenan
Mr. and Mrs. Thomas Kennedy
Ms. Susan Kenney
Kersten Family Foundation
Mr. and Mrs. Peter Keseric
Mr. and Mrs. James P. Kiefer
Mr. and Mrs. William Kies
Kies Consulting LLC
Mrs. Robert Kimball
Ms. Marie Kimmel and
Ms. Rose Riemer
Kipnis Rosen & Bloom, Ltd.
Drs. Diane and William Kleiber
Mr. and Mrs. Mathias A. Klein III
Allan & Millicent Kleinman
Family Foundation
Mr. and Mrs. William Klettke
Ms. Monica Davidson Klinke
Mr. James B. Klutznick
Mr. and Mrs. Joseph Kohberger
Jane, Charles and Nick Kolb
Ms. Karen S. Kolodzey
Mr. and Mrs. Bernard Kompare
Mr. and Mrs. Alan Koplar
Kottke Associates, LLC
Ms. Julie Kraemer
Mrs. Robert Kramer
Mr. and Mrs. Ronald Krass
Ms. Anita Krichmar and
Mr. Sam Brooks
Dr. and Mrs. Norton Kristy
Mr. David Kruchko
Mr. and Mrs. T. Chris Krueger, Sr.
Ms. Gale J. Kryzak
Mr. John A. Kuhlman, Jr.
Pat and Gib Kurschner
Ms. Victoria J. Kusbel
Mr. Louis V. LaBelle
Lakeside International Auto
Service, Inc.
Ms. Cathy Z. Lalich
Ms. Maureen B. Lampert
Lester Lampert Inc.
Mr. and Mrs. Charles Lamphere
Ms. Mary Patricia Landa
Dr. Albert W. Lang
Ms. Kathy Lange and
Mr. Tom Lefebvre
Ms. Mary Langerud
Jennifer and Joey Lansing
Ellyn and Andy Lansing
Mr. and Mrs. Joseph Lanzillotti
Mr. and Mrs. Howard Lapides

Mr. and Mrs. Daniel Larkin
Mr. and Mrs. Raymond O. Larsh
Mr. Jerry Latherow and
Kersten Stenson
Mrs. Leonard Lavin
Mr. and Mrs. Jay Lawrence
Dr. Michelle LeBeau
and Dr. Robert Harwood
Lee Lumber & Building Material
Corp
Mr. and Mrs. Thomas J. Lee
Mr. and Mrs. Peter Leibowitz
Leibowitz Realty Group, Inc.
Ms. Amalia T. Lemar
Ms. Iris D. Lemmer
Ms. Sue Leuschke
Ms. Judy Lev
Ms. Renee Leveille
Mr. and Mrs. Lawrence Levin
Ms. Margot B. Levin
Dr. and Mrs. Laurence Levine
Mrs. Donald Levinson
Mr. and Mrs. Carl B. Levitt
Mr. and Mrs. James A. Levy
Mr. and Mrs. Paul Lewis
Mrs. Janet Lewis
Mr. William F. Lewis
and Ms. Janie M. Swenson
Mr. Jay D. Lewis
Mr. and Mrs. Dan Lewis
Ms. Cora N. Lewis
Mr. David L. Liebman, Jr.
Mr. and Mrs. David L. Liebman III
Mr. and Mrs. John H.
Lindemulder
Mr. and Mrs. Matthew Lindland
Mrs. Edward Liphardt
Ms. Theresa Guarino Lipo
Lawrence and Phyllis Lipsky
Mr. Hugo A. Lorenz
Mr. David S. Lott
Mr. and Mrs. Mark Lozier
Mr. and Mrs. James Luebchow
John P. Lynch Family Foundation
Ms. Katherine R. Lynch
Mr. and Mrs. Douglas W. Lyons
Ms. Margaret A. Lyons
Kevin MacMillan
Ms. Anat Madanes
Mrs. Carl J. Madda
Magical Elves, Inc.
Ms. Ellen Magrini
Mr. and Mrs. Wm. G. Timothy
Mahon
William R. and Norma Maki
Mr. Stephen A. Malato
Corinne and Marshall Malina
Mr. and Mrs. J. Malsch
Mr. Charles Manker
Mr. and Mrs. Michael Mansour
& Family
Mr. and Mrs. Steve Manus
Mr. and Mrs. Tony Manzari
Mariani Enterprises, Inc.
Mr. James R. Marino
Mr. and Mrs. Raymond J.
Markman
Stephanie and Jonathan Marks
Ms. Jill Marotta
Mr. Bradford Marshall
Darcy and Malcolm Marshall
Mr. and Mrs. Richard J. Marshall
Ms. Maureen A. Marthaler
Mr. and Mrs. Arnold Martin
Mr. Donald M. Martin
Mr. and Mrs. Ronald A. Marwitz
Mr. and Mrs. John Mathias
Norma and Fred Maxson
Ms. Florence B. Mayefsky
Mahmoud Mazaheri
Mr. and Mrs. Douglas L.
McCarroll
Ms. Mary T. McCarthy
Ms. Suzanne F. McCullagh
Ms. Patsy McCurdy
Mr. and Mrs. John M. H.
McDermott
Mr. and Mrs. James McDonough
Mr. John P. McEnaney
Mr. and Mrs. Roger McEniry
Ms. Anita Marie McFarlane
Mr. Derrick E. McGavic
McGrath Lexus of Chicago
Ms. Rosemary P. McLean
McMaster-Carr Supply Company
Mr. Paul R. McNaughton
Major Elizabeth M. Mehlin
Mr. and Mrs. Emery G. Meiley
Ms. Rita Meltzer
Merrill Lynch & Co.
Foundation, Inc.
Mr. and Mrs. Richard Merrill
Mr. Timothy Merrill
and Ms. Reggie Beckman
Koenig & Strey / GMAC
Mesirow Financial
Mr. and Mrs. Jonathan Metcalf
Mr. and Mrs. David J. Meyers
Mr. and Mrs. Robert Mignin
Mr. and Mrs. Jonathan Miller
Mr. and Mrs. Donald C. Miller
Ms. Carolynn J. Miller
Ms. Amy Miller
Ms. Roberta Eileen Miller
Mr. and Mrs. James C. Mills
Dr. Mary Molo and Mr. Steven
Molo
Ms. Marianne Monnin
Ms. Sue Montgomery
Mr. Michael Moore
Mr. Erwin More
Morgante-Wilson Architects, Ltd.
Mr. and Mrs. James Moriarity
Ms. Nancy E. Morrison
Mr. Sidney Moskowitz
Norman and Dolores Mostad
Ms. Margaret F. Mullett
Ms. Norine E. Mullins
Mr. and Mrs. Bruce Mumford
Ms. Joanne Murphy and
Mr. Joseph Contino
Ms. Michelle G. Nacker
Ms. Mary K. Nagle
Mr. and Mrs. Stephen J. Nardi
Mr. and Mrs. Thomas E. Neal
Mr. and Mrs. Scott Needham
Ms. Sylvia Neiberg
Mr. George Neubauer
Ms. Annmarie Neumeier
Ms. Patricia B. Newell
Ms. Christina Newenhouse
Mr. and Mrs. Thomas E.
Newman
Nexus Corporation
Ms. Marianne C. Nichols
Mr. and Mrs. James S. Nicol
Mr. and Mrs. Stanley Nitzberg
Mr. John A. Nolte and
Mr. Jon R. Accardo
The Northern Trust Company
Ms. Margaret O. Northey
Mr. and Mrs. Kent Novit
Ms. Elizabeth I. Nowicki
Ms. Maria E. Nowicki
Nuveen Investments
Oak Brook Bank
Kenneth Ochterski & Family
Mr. Patrick J. O’Donnell
Mr. Jeffrey S. O’Dwyer
Ogden Avenue Motors, Inc.
Mr. and Mrs. Bruce Olsen
Katherine L. Olson Charitable
Foundation
Mr. and Mrs. Thomas Emmet
O’Neill III
Mr. and Mrs. Robert Orbesen
Mr. and Mrs. James M. Orlin
Mr. and Mrs. James G. Orphan
Ms. Marie F. Osadjan and
Mr. Jim Cruger
Ms. Cherilyn K. Ovca
Mrs. Donald R. Owen
Ms. Jodiann Pacer
Mr. David W. Paczak
Mr. and Mrs. David Palmer
Mr. and Mrs. Edward A. Palmer
Mr. and Mrs. Dennis J. Parello
Ms. Krista Parkinson
Mr. and Mrs. Norman J. Patinkin
Mr. and Mrs. Harcourt S.
Patterson
Mr. and Mrs. Thomas G.
Patterson
Mr. and Mrs. Kirby Pearson
Ms. Georgy Ann Peluchiwski
Mr. and Mrs. Kenneth Perkins
Mr. and Mrs. James Perry
Perry Capital, LLC
Ms. Terry Pesek
Ms. Barbara Peskin
Mr. Robert Peters
Mr. and Mrs. Robert Peterson
Ms. Shirley M. Petry
William D. Petty, D.D.S.
Mr. and Mrs. Craig Phelps
Mr. Thomas A. Phillips
Mr. and Mrs. Heber Pierce
Ms. Amanda B. Pierce
Mr. and Mrs. John S. Pierce
Mr. and Mrs. Michael Pinzur
Mr. and Mrs. John J. Piva, Jr.
Ms. Wendy Planek
Ms. Mary A. Planek
Ms. Pamela S. Platt
Ms. Jacqueline Ann Plourde
Mr. and Mrs. Gordon Lee Pollock
Mr. and Mrs. Edward Pope
Mr. and Mrs. R. Clifford Potter
Ms. Barbara F. Potter
Mr. and Mrs. William P.
Prendergast
Ms. Maura S. Priem
The Private Bank
Mr. and Mrs. Peter Prokopowicz
The Puchalsky Family
Ms. Cheryl Rampage and
Mr. Larry LaBoda
Mr. and Mrs. John H. Rannells
Mr. Paul Rathe
Mr. and Mrs. Christopher G.
Reagan
Ms. Loretta M. Reed
Residential Kitchen Design
Resource Financial Corp.
Mr. and Mrs. Michael J. Revord
Mr. and Mrs. J. Christopher
Reyes
Mr. and Mrs. Tom Reynolds
Ms. Meg M. Reynolds
Ms. Mary Ellen Reynolds
Mr. Robert C. Ribits
Mrs. Craig Richardson
Richco, Inc.
Ms. Dolores M. Richert
Ms. Julie Ridenour
Ms. Connie Riemer
Mr. and Mrs. Gerald Ritter
Mr. and Mrs. Craig H. Ritter
Mr. and Mrs. Lawrence Rochell
Mrs. Frederick Roe
Mr. and Mrs. Scott T. Roelofs
Mr. and Mrs. Peter Rogers
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
19

Ms. Judith Ann Roland
Ms. Dona C. Roper
Ms. Ellen F. Rose
Mr. Richard Rosen and Family
Mr. and Mrs. Harry B. Rosenberg
Mr. and Mrs. Andrew Rosenfield
Ms. Marilyn S. Rosengarden
Drs. Marsha Rosner and
Robert Rosner
Mr. and Mrs. Warren N.
Rothman
Mr. Marc E. Rothman
Mrs. Dorothy B. Rothschild
Mr. and Mrs. Randall Rowe
Mr. and Mrs. Peter Rub
Mr. and Mrs. Arlen D. Rubin
Ms. Adele Rubin
Mr. and Mrs. Howard Rudolf
Ms. Lori Runquist
Rush North Shore Medical
Center/Noninvasive
Cardiovascular Services
Ms. Barbara J. Rush
Mr. and Mrs. Alan R. Ryan
Ms. Lauren E. Ryan
Mr. Michael W. Ryan
Ms. Elizabeth A. Ryan
Mr. Robert Y. Ryan
Mr. and Mrs. Jerrold M. Sadock
Mr. and Mrs. Edward Salomon
Mr. and Mrs. Bert Salzbrunn
Linda and Steve Salzman
Mrs. Gloria S. Samuelson
Ms. Sandra A. Sanford
Mr. and Mrs. Ronald Saslow
Mr. and Mrs. Frank C. Schell, Jr.
Allen H. Schiefelbein-Insurance
Ms. Linda Schiff
Mr. and Mrs. Robert L.
Schlossberg
Julie and Bob Schlossberg
Ms. Esther Schlutz
Andreas W. Schmalz
Mr. and Mrs. William F. Schmidt
Ms. Katharina Schmidt
Mr. and Mrs. Bernard J.
Schneider
Dr. Anne M. Schreiber
Ms. Mary Jo Schuler
Mr. and Mrs. Brian Schultz
Mr. and Mrs. Donald R. Schultz
Mr. and Mrs. Sheldon G. Schultz
Caryn and Bill Schuman
The Alan & Roslyn Schwartz
Foundation
Mr. Larry Schwartz
Mr. and Mrs. Richard D.
Schwartz
Scranton Gillette
Communications
Mr. and Mrs. Richard Scully
Sean Patrick’s Salon
Searl and Associates,
Architects, P.C.
Ms. Eloise V. Searl
Mr. and Mrs. Stephen P. Seder
Sedgwick / Detert, Moran &
Arnold
Mr. Verne P. Seehausen
Frances R. Seidman
Mr. and Mrs. Robin P. Selati
Ms. Elizabeth A. Shannon
Mr. and Mrs. Laurence Jay
Shapiro
Ms. Susan Sharpe and
Mr. Kenneth Lock
Mrs. Ilene Shaw
Ms. Stacey A. Shearer
Ms. Jean E. Sheridan
Mr. and Mrs. David Sherman
Ms. Barbara J. Shifley
Ms. Elaine Shifrin
Mr. and Mrs. Lloyd G. Shore
Ms. Gerri L. Shute
Mr. and Mrs. Alex G. Siegler
Mr. and Mrs. Jerry G. Silbert
Ms. Mary Silver
Yael and Howie Silverman
Mr. Rob Silverstein
Ms. Polly P. Sippy
Mindy and Gary Sircus
Mr. Robert Sirota
Ms. Elizabeth H. Skalitzky
Ms. Kathleen Skapek
Mr. and Mrs. Bernard Slinkman
Mr. Christopher M. Sloan
Mrs. Harry J. Smedley, Jr.
Mr. and Mrs. Michael G. Smith
Mr. and Mrs. Alan Smith
Mr. and Mrs. Daniel W. Snyder
Mr. and Mrs. Robert D. Sobel
Larry and Adina Sodomire and
Family
Ms. Kathryn M. Soja
Ms. Gwen Solberg
Mr. and Mrs. Glenn Solheim
Mr. and Mrs. James Solomon
Mr. and Mrs. Leonard H.
Solomon
Mr. Robert S. Soraparu
Mr. and Mrs. Chad Soren
Mr. and Mrs. Steven Sparks
Mr. and Mrs. David Speelman
Mr. and Mrs. Ray W. Spiegel
Candy and Tom Spiel
Mr. and Mrs. Kenneth S.
Spielman
Ms. Nancy Stankus
Sara and James Star
State Bank of Countryside
Mr. William J. Stegeman
Mr. and Mrs. Dwight D. Stein
Mr. and Mrs. Regan Stern
Ms. Nancy K. Sterwart
Mr. and Mrs. Josef Stibi
Professors Carolyn and Jack
Stieber
Mr. and Mrs. Roger Stone
Mrs. John C. Stone
Ms. Susan Stone
Ms. Mary Strahota
Mr. and Mrs. Alexander Stuart
Mr. and Mrs. Timothy Sullivan
Ms. Georgean Summers
Superior Mailing Services, Inc.
Susanin’s Saturday Auctions
Arlyn and David Sutton
Mr. and Mrs. John Svoboda
Ms. Olga Swiontek
William and Ruth Szabo
Mr. and Mrs. James Taich
Ms. Sara Takeuchi
Ms. Florence Leroy Tallent
Mr. Ernest E. Tallisman
Dr. Marvin E. Tazelaar
Team 1 Systems, Inc.
Mr. and Mrs. John E. Teles
Mr. and Mrs. Earl Temkin
Ms. Terry J. Thiese
Mr. and Mrs. Robert Thomas
Mr. and Mrs. Irv Thomas
Ms. Teresa M. Thompson
Mr. and Mrs. Roger J. Thomson
Ms. Diane S. Tielbur
Ms. Aldona Tokarski
Mr. and Mrs. Leon Tonelson
Mr. and Mrs. John Totten
Mr. and Mrs. William H. Towle
Ms. Anita E. Trainor
Mr. and Mrs. William D. Trecker
Ms. Mary P. Trecker
Mr. and Mrs. Howard Tullman
Mr. John L. Turner
Ms. Ruth E. Ultmann
Mr. and Mrs. Barry Ultmann
University National Bank
Gregory P. Van Schaack
Mr. and Mrs. Herman
Vandernaald
Mr. Karl H. Velde, Jr.
Veterinary Specialty Center
Mr. Nicholas Vogelzang
Mr. Gordon Vogt
Mr. and Mrs. Robert Von Halle
Ms. Nancy E. Voss
Kevin, Debbie, Ben & Jake Wade
Ms. Joan P. Waldron
Mrs. Kathleen B. Walgreen
Mr. and Mrs. Wally Wallis
Walsh Landscape Construction, Inc.
Mr. and Mrs. Charles Walsh, Sr.
Mr. and Mrs. Doug Walter
Mr. Morgan Wandell
Mr. and Mrs. Leonard Ward
Mr. and Mrs. William Warning
Mr. Morris S. Weeden
Weible/Cahill & Forker, LLC
Mr. and Mrs. Charles Weinles
B. Weinstein Associates
Mr. and Mrs. Ronald Weismehl
Mr. and Mrs. David C. Wenger
Mr. and Mrs. Robert Werner
Ms. Coleen G. Werner
Mr. and Mrs. Jeffrey Wessel
Ms. Carol J. Wetmore
Mr. and Mrs. Jeffrey A. Wheatley
Ms. Helen E. Whelan
Mr. and Mrs. Thomas White
Mr. and Mrs. Emmett White
Mr. and Mrs. John White
Ms. Maralee Sabath Wicks
Ms. Dorothy M. Wicoff
Mr. and Mrs. Neale A. Williams
Mr. and Mrs. J. Reading Wilson, Jr.
Mr. and Mrs. Robert C. Winans, Jr.
Mr. and Mrs. L. Woerdehoff
Mr. and Mrs. Thomas L.
Woerdehoff
Mr. and Mrs. Arnold R. Wolff
Mr. and Mrs. Jay R. Wolff
Mr. and Mrs. Lee Wolfson
and Ms. Laura Wolfson
Mr. and Mrs. Robert Wolkoff
The Yates Family
Ms. Anne Yeager
Mr. and Mrs. Charles G. Yorke
Mr. and Mrs. John F. Zabriskie
A. W. Zengeler Cleaners, Inc.
Ms. Gloria J. Zieve
Mr. Morton H. Ziker
Mr. and Mrs. William
Zimmerman
Ms. Marjorie Zolla
Ms. Barbara Zoub
Ms. Shelley E. Zuraw
Mr. and Mrs. Leon Zygmun

Boards and Auxiliaries
As this year’s annual report makes clear, the members of the University of Chicago Cancer Research Center are
successfully fighting cancer in the lab, the clinic and the community. Among their most valuable allies in these
efforts are the University of Chicago Cancer Research Foundation and other supporting boards and auxiliaries.
We see the evidence of their participation in state-of-the-art equipment, enhanced hospital and laboratory facilities,
fellowships for young scientists, and essential funding for some of our most distinguished researchers. These scientists
rely on this essential support because it provides them with the freedom necessary to pursue their most visionary
investigations and break new ground.
The next several pages introduce you to these committees and their members and review some of the many ways they
have supported cancer research in FY 2004.
The Board
of Trustees
Ruth Ann Gillis McGuinnis,
President
*Mrs. William Adams IV
John Atchison
*Mrs. Ted Brandt
*Rita Brezina
Mrs. Seymour A. Cohen
Richard W. Cusack
John W. Derse, Jr.
Richard L. Duchossois
Thomas J. Duckworth
Ronald L. Duitsman
Mrs. Leonard S. Florsheim, Jr.
Wende L. Fox
Stanford J. Goldblatt
Charles P. Hammersmith, Jr.
Mrs. Michael Klein
John A Kuhlman, Jr
Mrs. Orion Samuelson
T. Stephen Thompson
Barton G. Tretheway
*ex officio
Honorary Trustees
Seymour A. Cohen
John D. Gray
William H. Hartz, Jr.
Leonard H. Lavin
J. Clifford Moos
Mrs. Timothy H. Ubben
The Women’s
Board
Mrs. William Adams IV, President
Mrs. Alexander Anagnost
Mrs. Helena Appleton
Mrs. John R. Atchison
Allison Bacon
Laurie Bay
Mrs. Thomas M. Begel
Margaret Benjamin
Mrs. Darcy Robert Bonner
Janna Bounds
Mrs. James Brady
Mrs. Harris C. Brumfield
Mrs. Bernard Burnstine
Mrs. Michael Joseph Busch
Mrs. Benjamin D. Chereskin
Mrs. Gregory Chun
Ms. Linda Burns Coleman
Mrs. Robert Conrad
Mrs. Fred Cook
Mrs. Thomas L. Cox
Mrs. Michael Crane
Mrs. J. Michael Crouch
Mrs. Richard W. Cusack
Mrs. Andrew Da Miano
Mrs. Thomas C. D’Aprile
Ms. Rebecca Davidson
Mrs. John Derse
Mrs. David W. Devonshire
Mrs. W. Brinkley Dickerson, Jr.
Mrs. Jeffrey Diermeier
Ms. Suzette Flood
Ms. Susan Florence-Smith
Mrs. Fahey Flynn
Mrs. David W. Fox, Jr.
Mrs. Edward Gillette
Mrs. Thomas T. Hall
Mrs. Thomas L. Hardin
Mrs. Charles Harrold III
Mrs. Steven S. Helms
Lesli K. Henderson
Mrs. William J. Hokin
Mrs. Steven Edward Johnson
Mrs. R. Stuart Johnstone
Mrs. Thomas Eric Kilcollin
Mrs. Donald A. King, Jr.
Mrs. Bernard J. Kompare
Ms. Josephine Krug-Schulte
Kristine Kurschner
Marie Lawton
Ms. Amy Mazzolin
Mrs. Andrew McGaan
Robin Josephs McGarvey
Astrid A. McKinnon
Mrs. Edward J. Miller
Mrs. David Nuelle
Mrs. Stuart Oran
Ms. M. Bliss Packer
Mrs. Kirby Pearson
Mrs. Heber Pierce
Mrs. Gordon Lee Pollock
Mrs. Thomas Reusché
Mrs. Frederick Roe
Mrs. Frank C. Schell, III
Mrs. James H. Schink
Mrs. Richard Scully
Barbara Sessions
Mrs. Barton Glenn Tretheway
Ms. Nancy Voss
Mrs. Keith Ward
Mrs. William Wardrop
Mrs. Michael Werner
Ms. Alice Williams-Verhoeven
Sustaining Members
Mrs. Gail Kirk Bennett
Dr. Geraldine Balut Coleman
Mrs. Robert A. Conger
Mrs. Gustav Horschke
Phyllis Horwitz
Mrs. Robert Kimball
Mrs. Robert Kramer
Mrs. Donald Levinson
Mrs. Edward Liphardt
Mrs. Michael McGuinnis
Mrs. Robert Mignin
Mrs. R. Clifford Potter
Mrs. Sandra Reese-Stepke
Mrs. Craig Richardson
Mrs. Harry J. Smedley, Jr.
Mrs. John C. Stone
Mrs. Leon E. Zygmun
Honorary Members
Mrs. Walter E. Auch
Mrs. Wendy Becker-Payton
Mrs. Robert R. Bell
Mrs. R. Ford Bentley
Mrs. Sharon Brix
Mrs. Seymour A. Cohen
Mrs. Alix Engel
Mrs. Leonard S. Florsheim, Jr.
Mrs. Maurice Goldblatt
Mrs. Edmund Laun-Knauf
Mrs. Arthur MacQuilkin
Mrs. Charles W. Tallent
Mrs. Charles Walgreen III
The Women’s Board has become central to the pursuit
of the Center’s mission. This year the members exceeded
their record successes of past years and provided the
Center with a remarkable donation of $625,000.
This funding is being used for a variety of purposes.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
21

The Ben May Institute for Cancer Research
Since 1951, the Ben May Institute has advanced cancer research by addressing fundamental issues in biological
sciences. As Marsha Rosner, PhD, the Institute’s current director, has said, “Every advance in the war against cancer
has its origin in basic scientific research. High quality research leads to new treatments and eventually cures.” As this
report documents in the numerous references to its accomplishments, the Institute sets a standard for excellence.
The Women’s Board has long been a staunch supporter of the Institute. This year, the Board is focusing its contributions
in support of an innovative effort to create a core laboratory dedicated to enhancing our drug discovery program.
Geoffrey Greene, PhD, is leading the development of this facility. The Women’s Board’s funding is underwriting
recruitment of a talented professional to manage this new facility.
Advanced Technology and Resources for the Genetics,
Proteomics and the Drug Discovery Continuum
Research has opened a vast new world of scientific discovery. We are searching for solutions in the minute worlds of
individual cells, genes, chromosomes and proteins. Such exploration requires instruments and materials of incredible
sophistication and precision. In 2004, the Women’s Board enabled the acquisition of resources that support every step
of the process, which begins with highly specialized analysis of genes and proteins and culminates in the development
of innovative drug therapies.
For example, the Board provided funds for matrix-assisted, laser-desorption-ionization, time-of-flight (MALDI-
TOF) mass spectrometry. This complex, innovative technology for protein profiling allows our researchers to compare
cancerous and normal tissue and serum samples. The Board’s past support of the Human Tissue Core helps ensure
that our researchers have tissue samples and derivatives (i.e. RNA, DNA and proteins) available for study. This year,
its contribution is helping staff this facility with a qualified technologist. Thanks to the Board, our scientists also have
a new bioreactor that is used to obtain target proteins for research.
Drug screening is at the heart of drug discovery. This process enables researchers to identify the compounds most
effective for inhibiting the growth of tumors. This year, the Board supported the purchase of libraries containing 50,000
compounds for study. High performance liquid chromatography (HPLC) is an analytical technique that enables
precise quantification of drug levels in plasma, serum and urine samples from patients treated with investigational
drugs. By enabling the Center to acquire this advanced technology, the Board has enhanced the Center’s capacities
for analyzing new compounds and determining the most effective, least toxic dosages of investigational drugs.
Committee on Cancer Biology
The Board has long been a friend of the Committee on Cancer Biology, which is one of the premier cancer research
degree-granting programs in the nation. Private funding from the Women’s Board ensures that Committee is able
to attract and educate the most promising students in the world. This year, the Women’s Board is helping in the
recruitment of young scholars who will bring fresh perspective and enthusiasm to the pursuit of the Center’s mission.
cGMP Facility
The University of Chicago cGMP (current Good Manufacturing Practice) Core Facility provides investigators with a
state-of-the-art facility in which to prepare cellular-based products and drugs for the treatment of cancer patients. This
facility must meet daunting standards for quality. In 2004, the Women’s Board provided funding for the recruitment
of a top professional to lead a strong quality assurance program. The Food and Drug Administration (FDA) requires
that such a program is in place before therapies can be released for patient treatment.
UCCRC AdvanceLink
The Women’s Board has been instrumental in the development of the AdvanceLink information technology system,
which is proving invaluable in the management of the voluminous information generated by our clinical trials
program. Managing this data is essential to protecting patients, meeting regulatory requirements, and guaranteeing
effectiveness. This database allows all researchers and their teams to audit, analyze, and report data more effectively
and efficiently. This advanced tool frees them to focus on their patients.

The Auxiliary Board
Elizabeth Brandt, President
Celeste Alcock
Susan Bondurant
Jackie Bossu
Maggie Flanagan
Laurie Foster
Margo Calvetti Frost
Jan Grimes
Nancy Gupta
Annette Hickman
Terri Kingdom
Maggie Kinney
Becky Kolleng
Darlene Landsittel
Mary Marnell
Jo Ann McKibben
Andrea Montross
Nancy Napalo
Jan Peterson
Tam Rustin
Laurie Shiel
Ginger Stambaugh
Laura Thomson
Liz Williams
Christine Youngberg
Sustaining Members
Leigh Beith
Shirley Bennett
Barbara Bridges
Anne Collins
Elizabeth Crawford
Anne Dougherty
Ethel Fox
Susan Fraley
Jane Hemmings
Jan Hetherington
Margaret Jacoby
Joan Lancaster
Betty Ann Manganaro
Linda McCann
Jan McKnight
Mary O’Connell
Helen Panje
Mary Helen Ray
Patti Tyska
Mary Clare White
Honorary Members
Cherri Allen
Barbara Devlin
Carol Lynnes
In 2004, the Auxiliary Board provided $90,000 to support three cancer researchers: Mark D. McKee,
MD; Karen M. Frank, MD, PhD; and Miriam B. Rodin, MD, PhD.
Dr. McKee is exploring new approaches to immunotherapy. Many studies have focused on developing vaccines that
stimulate T cells (a type of white blood cells) to attack tumors. Dr. McKee’s approach skips many of the intermediate
steps and is less problematic than the more common method. He uses gene therapy to modify the patient’s own
T cells and return them to the body to attack the cancer cells. This more efficient treatment also provides new
opportunities to examine how cancer-fighting T cells travel through the body and interact with tumors.
Dr. Frank investigates both the immune system and the mechanisms of cancer development. Her research studies
how the immune system creates antibodies to fight infections. This process, managed by white blood cells, breaks
DNA and rearranges it in a controlled manner. Leukemia or lymphoma can result if the process fails to rearrange
the DNA correctly. She also studies how defects in DNA repair pathways create abnormal genes that can lead to the
development of cancer in any organ. Understanding these fundamental cellular mechanisms is the first step in the
process of developing more targeted therapeutic strategies.
Dr. Rodin studies the effects of cancer treatments on the memory, attention and thinking faculties of cancer survivors.
She and her team also have implemented a clinical database useful in the examination of the health care needs and
health outcomes of elderly cancer survivors.
The Associates Board
Rita Brezina, President
Greg Bannon
Amy Will Brumfield
Holly Ledler Cortes
Megan Dawson
Megan DeRoma
Sadie Everett
Jim Foster
Amy Herron
Kristen Karczewski
Marianne Monnin
Amanda Pierce
Elizabeth Ryan
Lauren Ryan
Michael Ryan
Taaron Silverstein
Rob Soraparu
Aldona Tokarski
Nick Vogelzang, Jr.
The Associates Board provided $110,000 in funding to support the cGMP facility and
mesothelioma research.
Although it is the UCCRF’s newest Board, the Associates Board has already made significant contributions
to advance cancer research and has helped The University of Chicago maintain its reputation as a pioneer in
the study and treatment of malignant mesothelioma. It has provided funding support for Hedy L. Kindler,
MD, Ravi Salgia, MD, PhD, and the cGMP facility, which this report describes on page 22.
The Junior Cancer League
Mrs. Kenneth Rabin, President
The League supports the work of Dr. Melvin L. Griem.
Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004
23

Income
UCCRF Beginning Balance July 1, 2003 $434,984
UCCRF Contributions
Unrestricted 116,027
Restricted Funds 522,060
638,087
Auxiliaries’ Income
Women’s Board 890,863
Auxiliary Board 90,000
Associates Board 105,969
Junior Cancer League 19,000
1,105,832
Endowment Income
UCCRF Board of Trustees 4,447
Simon M. Shubitz 16,306
2003-2004 Financial Report
Operating Expenses and Allocations $1,822,302
20,753 Total Income $1,764,672
Ending Balance June 30, 2004 $377,354
Operating Expenses and Allocations
Operating
UCCRF 167,620
Women’s Board 234,976
Associates Board 8,943
411,539
Allocations
Research & Faculty Support 549,798
Women’s Board 641,965
Auxiliary Board 90,000
Associates Board 110,000
Junior Cancer League 19,000
1,410,763
UCCRC Funding Sources
Funding Agency
NCI 28,933,793
Other NIH 28,848,763
ACS 1,354,720
NSF 68,955
Other Peer Reviewed 5,261,496
Industry Non Peer Reviewed 12,754,002
Other Non Peer Reviewed 17,077,250
Gifts/Endowments 6,847,473
101,146,452

Help Us, Keep Seeking!
To learn more about cancer research at the University of Chicago and how
you can help our researchers pursue promising avenues of investigation that
would otherwise remain unexplored, please contact Mary Ellen Connellan,
Executive Director, University of Chicago Cancer Research Foundation, at
(773) 834-7490 or mconnell@medicine.bsd.uchicago.edu
A donation to the University of Chicago Cancer Research Foundation is an
investment in one of the nation’s leading facilities for scientific inquiry and
will help people here at home and around the world.
Donations by check may be made to:
The University of Chicago Cancer Research Foundation
5841 South Maryland Avenue, MC 1140
Chicago, IL 60637
All gifts are tax deductible as provided by law.
The University of Chicago
Cancer Research Center
Michelle M. Le Beau, PhD
Director, the University of Chicago Cancer Research Center
Professor of Medicine and Human Genetics
Marcy A. List, PhD
Director for Administration
Scientific Director, Cancer Clinical Trials Office
Marsha R. Rosner, PhD
Deputy Director
Charles B. Huggins Professor and
Director, Ben May Institute for Cancer Research
Professor of Neurobiology, Pharmacology and Physiology
Everett E. Vokes, MD
Deputy Director
John E. Ultmann Professor of Medicine and
Director, Section of Hematology/Oncology
Professor of Radiation and Cellular Oncology
Geoffrey L. Greene, PhD
Associate Director for Basic Sciences
Virginia and D. K. Ludwig Professor and
Associate Director, Ben May Institute for Cancer Research
Professor of Biochemistry and Molecular Biology
Chair, Committee on Cancer Biology
Mark J. Ratain, MD
Associate Director for Clinical Sciences
Leon O. Jacobson Professor of Medicine
Chair, Committee on Clinical Pharmacology and Pharmacogenomics
Paul J. Butera, PhD
Director for Communications
Mary Ellen Connellan
Director, the University of Chicago Cancer Research Foundation
Jay Lewis
Director for Informatics and Technology
Maria Reyes
Director for Finance
Seeking Cancer Cures
On All Fronts
Editor:
Paul J. Butera, PhD
Design and Printing:
Pixel Print Graphics
©2004 The University of Chicago Cancer Research Center.
All rights reserved.

5841 South Maryland Avenue, MC1140, Chicago, IL 60637
www.uccrc.org